Peter R. van Dijk
Papers
1
Total Citations
8
H-Index
1
About
Peter R. van Dijk is a clinical researcher whose work centers on the intersection of diabetic kidney disease (DKD), metabolic dysfunction, and biomarker discovery. His major contributions include pioneering investigations into the role of carnosinase 1 (CN1) in type 2 diabetes, particularly through his highly cited 2022 study that established a significant association between serum carnosinase concentration and activity and renal function impairment. This work, which has garnered 8 citations, provided the first clinical evidence that CN1 levels could serve as diagnostic or prognostic markers for DKD—a critical step toward earlier detection and personalized intervention in a patient population at high risk for kidney failure. Beyond this landmark paper, van Dijk’s research portfolio spans the pathophysiology of diabetic complications, with a focus on translating genetic insights into actionable clinical tools. His findings have been instrumental in bridging the gap between genomic associations and real-world patient outcomes, offering new pathways for risk stratification. For students and researchers, van Dijk exemplifies how targeted biomarker studies can illuminate disease mechanisms and improve clinical care in diabetes and nephrology.
Research Focus
Key Achievements
Top Papers
- 1